Preview Mode Links will not work in preview mode

This Week in Cardiology

Mar 19, 2021

COVID-19, Fish Oil and AF risk, SGLT2 inhibitors and renal outcomes, and TAVR vs SAVR are the topics discussed by John Mandrola, MD, in this week’s podcast.


EMA Launches Review of Clot Risk With AstraZeneca COVID Vaccine

AZ Vaccine Safe Overall but Questions Remain over Unusual Clots

Fish Oil and AF

Dose-Related AF Risk With Omega-3 Fatty Acids?

Effect of Marine Omega-3 Fatty Acid and Vitamin D Supplementation on Incident Atrial Fibrillation

Omega-3 Fatty Acids and Atrial Fibrillation

SGLT2i and Renal Outcomes

Ertugliflozin: Renal Benefits in Additional VERTIS CV Analyses

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial


TAVR vs SAVR in Low-Risk Patients: What We Do and Don't Know

Mortality in trials on transcatheter aortic valve implantation versus surgical aortic valve replacement: a pooled meta-analysis of Kaplan-Meier-derived individual patient data

Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk

Five-Year Outcomes of Transcatheter or Surgical Aortic-Valve Replacement

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

Questions or feedback, please contact